Faron Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company focused on immunotherapies for cancer, has announced the results of its extraordinary general meeting (EGM). The EGM approved all proposals put forward by the Board of Directors, including the confirmation of seven members on the Board. Christine Roth and Marie-Louise Fjllskog were elected as new members. The EGM also approved an amendment to the Option Plan 2015, extending the subscription period for shares based on options by two years until September 30, 2025. The minutes of the EGM will be available on the company's website from October 5, 2023.